Clinuvel Pharmaceuticals Limited (CUVL)
NASDAQ: CUVL · Real-Time Price · USD
5.95
+0.07 (1.19%)
At close: Sep 11, 2026, 4:00 PM EDT
5.95
0.00 (-0.08%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Clinuvel Pharmaceuticals Revenue
In the fiscal year ending June 30, 2026, Clinuvel Pharmaceuticals had annual revenue of 94.02M AUD, down -1.05%. Clinuvel Pharmaceuticals had revenue of 57.09M in the half year ending June 30, 2026, with 3.10% growth.
Revenue (ttm)
94.02M AUD
Revenue Growth
-1.05%
P/S Ratio
4.47
Revenue / Employee
5,876,525 AUD
Employees
16
Market Cap
290.78M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 94.02M | -993.17K | -1.05% |
| Jun 30, 2025 | 95.02M | 6.84M | 7.76% |
| Jun 30, 2024 | 88.18M | 9.86M | 12.59% |
| Jun 30, 2023 | 78.32M | 12.60M | 19.17% |
| Jun 30, 2022 | 65.72M | 17.40M | 36.02% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Fulcrum Therapeutics | 80.00M |
| Bicycle Therapeutics | 61.21M |
| Sutro Biopharma | 45.70M |
| ProQR Therapeutics | 21.05M |
| Pyxis Oncology | 11.04M |
| Fate Therapeutics | 6.49M |
| SAB Biotherapeutics | 114.70K |
CUVL News
- 15 days ago - Clinuvel Pharma FY26 Profit Slips 6%; Maintains A$0.05 Dividend; Shares Slide - Nasdaq
- 16 days ago - Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2026 - Transcripts
- 16 days ago - Clinuvel Pharmaceuticals Annual report: H2 2026 - Filings
- 16 days ago - Clinuvel Pharmaceuticals Earnings release: H2 2026 - Filings
- 16 days ago - Clinuvel Pharmaceuticals Slides: H2 2026 - Filings
- 16 days ago - A decade of profitability provides foundation for CLINUVEL's U.S. expansion - GlobeNewsWire
- 7 weeks ago - CLINUVEL implements strategic reorganisation to refocus on U.S. markets - GlobeNewsWire
- 7 weeks ago - CLINUVEL's ADS to commence trading on Nasdaq - GlobeNewsWire